HADEA/2023/OP/0036 – Speed up the Development of and Access to Innovative Medical Countermeasures

4 Loselaut Bekanntmachung

1. Vaccines to Combat Antimicrobial Resistance (AMR)

   Laufzeit ab Signal

   Lot 1 of this call aims to speed up the development of vaccine candidates targeting bacterial infections as an alternative treatment strategy to address the rising incidence of AMR.The identified vaccine candidates shall be designed to target bacteria belonging to at least one of the twelve bacterial families classified as ‘priority pathogens’ in the 2017 WHO Bacterial Priority Pathogens List. The

2. Broad Spectrum Antivirals against Respiratory Diseases

   Laufzeit ab Signal

   Lot 2 will support the development of broad-spectrum antivirals targeting respiratory RNA viral families, such as Paramyxo-, Orthomyxo and Coronaviridae.The antivirals subject of this call shall aim toȘ1. directly block viral targets and function (direct-acting antivirals);2. have an anticipated efficacy against multiple species or genera in at least one, but preferably several viral families;3. b

3. Broad Spectrum Antivirals Targeting Viral Families Known for Causing Viral Haemorrhagic Fever (VHF)

   Laufzeit ab Signal

   Lot 3 will support the development of broad-spectrum antivirals targeting viral families known for causing viral haemorrhagic fever (VHF), such as Arena-, Bunya-, Flavi-, Filoviridae.The antivirals subject of this call shall aim to:1. directly block viral targets and function (direct-acting antivirals);2. have an anticipated efficacy against multiple species or genera in at least one, but preferab